June 30–July 3, 2018
RAI Amsterdam, The NetherlandsRegister
A New Path Forward—Mass Cytometry and Microfluidics for Translational Cancer Research
Fluidigm is committed to empowering the cancer community with research tools for the comprehensive interrogation of immune cell function and the tumor microenvironment. Using proven mass cytometry and microfluidic technologies, we provide workflows to identify cell signatures and characterize changes in cellular phenotypes at single-cell resolution. Whether you seek to target new biomarkers and pathways or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you identify new insights to reach your next research breakthrough. Together we will transform the future of cancer care.
On July 2, as part of the 25th Biennial Congress of the European Association for Cancer Research, Fluidigm will host a symposium focused on our new Imaging Mass Cytometry™ and our powerful Helios™ mass cytometry system. We will also present our Biomark™ HD platform, which enables methylation analysis from FFPE samples as well as cell-free DNA from plasma.
|When:||Monday, 2 July
|Marie-Laure Yaspo, PhD
Max Planck Institute for Molecular Genetics, Otto Warburg Laboratory, Gene Regulation and Systems Biology of Cancer, Germany
|Towards truly personalized medicine: spatially resolved omics exploring the tumor and its microenvironment|
|Carsten Krieg, PhD
Assistant Professor, Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC
|Single-cell proteomics using mass cytometry: heating up the basics to master biomarker discovery|
|Andreas Weinhäusel, PhD
Senior Scientist and Thematic Coordinator, Austrian Institute of Technology
|High-throughput DNA methylation analysis for cancer biomarker development using the Fluidigm Biomark HD system|
Visit us at Fluidigm Stand No. 66
30 Jun–3 July 2018
RAI Amsterdam, Netherlands
For Research Use Only. Not for use in diagnostic procedures.